Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study
Authors
Keywords
-
Journal
Orphanet Journal of Rare Diseases
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-03
DOI
10.1186/s13023-019-1077-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of everolimus in patients younger than 12 months with congenital subependymal giant cell astrocytoma
- (2018) Ichiro Kuki et al. BRAIN & DEVELOPMENT
- The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives
- (2018) Susanne Schubert-Bast et al. EPILEPSY & BEHAVIOR
- Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience
- (2018) Darcy A. Krueger et al. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
- TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients
- (2017) John C. Kingswood et al. Orphanet Journal of Rare Diseases
- Regression of Neonatal Cardiac Rhabdomyoma in Two Months Through Low-Dose Everolimus Therapy: A Report of Three Cases
- (2017) Jeng-Sheng Chang et al. PEDIATRIC CARDIOLOGY
- Assessment of tumors in children with tuberous sclerosis: a single centre’s experience
- (2017) Suna Emir et al. TURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICS
- Everolimus-induced near-resolution of giant cardiac rhabdomyomas and large renal angiomyolipoma in a newborn with tuberous sclerosis complex
- (2016) Massimo Colaneri et al. CARDIOLOGY IN THE YOUNG
- Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
- (2016) Jacqueline A French et al. LANCET
- Accelerated Cardiac Rhabdomyoma Regression with Everolimus in Infants with Tuberous Sclerosis Complex
- (2016) Fatou Aw et al. PEDIATRIC CARDIOLOGY
- Tuberous Sclerosis Complex Associated with Vascular Anomalies or Overgrowth
- (2016) David Jenkins et al. PEDIATRIC DERMATOLOGY
- Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation
- (2016) Su-Kyeong Hwang et al. Molecular Brain
- Everolimus for subependymal giant cell astrocytoma: 5-year final analysis
- (2015) David N. Franz et al. ANNALS OF NEUROLOGY
- Oral Everolimus for Treatment of a Giant Left Ventricular Rhabdomyoma in a Neonate-Rapid Tumor Regression Documented by Real Time 3D Echocardiography
- (2015) Robert Wagner et al. ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES
- Neurological and neuropsychiatric aspects of tuberous sclerosis complex
- (2015) Paolo Curatolo et al. LANCET NEUROLOGY
- Use of mTOR Inhibitor Everolimus in Three Neonates for Treatment of Tumors Associated With Tuberous Sclerosis Complex
- (2015) Isabelle Goyer et al. PEDIATRIC NEUROLOGY
- Regression of massive cardiac rhabdomyoma on everolimus therapy
- (2015) Steven G. Hoshal et al. PEDIATRICS INTERNATIONAL
- Congenital focal lymphedema as a diagnostic clue to tuberous sclerosis complex: report of two cases diagnosed by ultrasound
- (2015) Sodai Hoshiai et al. SKELETAL RADIOLOGY
- Prenatal diagnosis of giant cardiac rhabdomyoma in tuberous sclerosis complex: a new therapeutic option with everolimus
- (2015) E. Mlczoch et al. ULTRASOUND IN OBSTETRICS & GYNECOLOGY
- Lymphedema in tuberous sclerosis complex
- (2014) Alexandra L. Geffrey et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- Everolimus treatment of a newborn with rhabdomyoma causing severe arrhythmia
- (2014) Funda Öztunç et al. CARDIOLOGY IN THE YOUNG
- Regression of Symptomatic Multiple Cardiac Rhabdomyomas Associated with Tuberous Sclerosis Complex in a Newborn Receiving Everolimus
- (2014) V. Do an et al. JOURNAL OF TROPICAL PEDIATRICS
- Rapid Regression of Left Ventricular Outflow Tract Rhabdomyoma After Sirolimus Therapy
- (2014) C. Breathnach et al. PEDIATRICS
- mTOR inhibition improves immune function in the elderly
- (2014) J. B. Mannick et al. Science Translational Medicine
- Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
- (2013) Darcy A. Krueger et al. ANNALS OF NEUROLOGY
- Wide spectrum of clinical manifestations in children with tuberous sclerosis complex – Follow-up of 20 children
- (2013) Roland R. Mettin et al. BRAIN & DEVELOPMENT
- Congenital Segmental Lymphedema in Tuberous Sclerosis Complex With Associated Subependymal Giant Cell Astrocytomas Treated with Mammalian Target of Rapamycin Inhibitors
- (2013) Giulia Prato et al. JOURNAL OF CHILD NEUROLOGY
- Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
- (2013) Hope Northrup et al. PEDIATRIC NEUROLOGY
- Congenital lymphedema: Another unique and gender specific stigmata of tuberous sclerosis?
- (2012) Kiron Sukulal et al. INDIAN PEDIATRICS
- Everolimus: A Challenging Drug in the Treatment of Multifocal Inoperable Cardiac Rhabdomyoma
- (2012) H. A. Demir et al. PEDIATRICS
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Congenital Lymphedema with Tuberous Sclerosis and Clinical Hirschsprung Disease
- (2010) MICHAEL LUCAS et al. PEDIATRIC DERMATOLOGY
- The natural history of epilepsy in tuberous sclerosis complex
- (2009) Catherine J. Chu-Shore et al. EPILEPSIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started